KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medicine and Oncology / 2022 / Cilt: 6 - Sayı: 1

Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers

Senem KARABULUT
Didem TASTEKİN
Meltem Selam TOPALGOKCELİ
Sayfa
12–15
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

All current developments will be reviewed in gastrointetsinal tract tumor treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Immunotherapies (ICI) are used alone, in combination with chemotherapy (CT) or targeted therapy in many cancers.
📊
Temel Bulgular & Veri:Immunotherapies (ICI) are used alone, in combination with chemotherapy (CT) or targeted therapy in many cancers.
💡
Sonuç & Katkı:All current developments will be reviewed in gastrointetsinal tract tumor treatment.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Immunotherapies (ICI) are used alone, in combination with chemotherapy (CT) or targeted therapy in many cancers. All current developments will be reviewed in gastrointetsinal tract tumor treatment.

🔖

Bu Makaleye Atıf Yap

KARABULUT, S., TASTEKİN, D., TOPALGOKCELİ, M. S. (2022). Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. Eurasian Journal of Medicine and Oncology, Cilt: 6 - Sayı: 1, 12–15. https://ajindex.com/articles/509458

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al; CheckMate 577 Investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384:1191–203
  2. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506–17
  3. Chen, Li-Tzong, Yoon-Koo Kang, Taroh Satoh, Yee Chao, Ken Kato, Hyun Cheol Chung, et al. A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data. J Clin Oncol 2020;38:383
  4. Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123–33
  5. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020;6:1571–80
  6. Moehler, M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L, et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol 2020;31:1191
  7. Boku N, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION- 4 (ONO-4538-37) study. Ann Oncol 2020;31:1142–215
  8. Kato K, Sun JM, Shah MA, Enzinger PC, Adenis A, Doi T, et al. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Ann Oncol 2020;31:1192–3
  9. National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers (Version 2.2021) and Gastric Cancers (Version 2.2021). Available at: https://www.nccn. org/professionals/physician_gls/pdf/esopha